Cue Biopharma, Inc.
CUENasdaq
$31.16
↑ +12.1%Jul 17 close · end-of-day
Price
1Y↑ +21.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$149.8M
Enterprise Value
$133.4M
P/E
8.7
P/S
4.6
P/B
6.9
EV/EBITDA
—
PEG
—
FCF Yield
-16.4%
Dividend Yield
—
Revenue (TTM)
$32.7M
Net Income (TTM)
-$19.5M
Free Cash Flow (TTM)
-$24.6M
Gross Margin
—
Operating Margin
-59.9%
Net Margin
-59.7%
ROE
-90.3%
ROIC
-296.2%
Debt / Equity
—
Net Cash
$16.4M
Return 1Y
+23.6%
Company profile
Cue Biopharma, Inc. develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
- CEO
- Daniel R. Passeri
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- Massachusetts
- Website
- cuebiopharma.com
Management & directors
- Borie Dominique ChristianChief Medical Officer
- Lin Shao-LeeChief Executive Officer
- Meluzio Michael VincentVP, Prin. Accounting Officer
- Ray SumitaChief Legal Compliance Officer
Roles derived from SEC Form 4 filings.
Earnings
CUE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$5.7M↑ +1250.6%
Diluted EPS-$1.08↓ -78.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.2M | $14.9M | $1.2M | $5.5M | $9.3M | $27.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$45.0M | -$43.7M | -$53.2M | -$52.1M | -$41.5M | -$26.6M |
| Net income | -$44.8M | -$44.2M | -$53.0M | -$50.7M | -$40.7M | -$26.6M |
| Diluted EPS | — | -$1.41 | -$1.49 | -$1.11 | -$0.72 | -$0.28 |
| Operating cash flow | -$32.5M | -$38.8M | -$41.8M | -$40.0M | -$36.3M | -$21.7M |
| Free cash flow | -$33.1M | -$39.8M | -$42.0M | -$40.0M | -$36.4M | -$21.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1428.0% | -292.6% | -4275.1% | -949.9% | -446.9% | -96.7% |
| Net margin | -1419.8% | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M | $3.3M | $1.6M | $421,000.00 | $3.0M | $2.1M | $21.9M | $5.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.4M | -$8.8M | -$9.6M | -$12.3M | -$8.6M | -$7.6M | $2.0M | -$5.4M |
| Net income | -$10.2M | -$8.7M | -$9.5M | -$12.3M | -$8.5M | -$7.4M | $1.6M | -$5.2M |
| Diluted EPS | -$0.20 | -$0.17 | -$0.10 | -$4.95 | -$0.09 | -$0.07 | $4.83 | -$1.08 |
| Operating cash flow | -$10.0M | -$7.5M | -$9.0M | -$8.2M | -$3.4M | -$9.0M | -$1.1M | -$10.9M |
| Free cash flow | -$10.0M | -$7.5M | -$9.0M | -$8.3M | -$3.4M | -$9.0M | -$1.1M | -$11.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -390.6% | -264.2% | -611.3% | -2921.4% | -292.3% | -353.4% | 9.0% | -94.1% |
| Net margin | -382.7% | -259.6% | -602.5% | -2911.4% | -287.1% | -346.6% | 7.2% | -91.1% |
Company news
Jul 13, 2026
- 7d agoHead and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightfinance.yahoo.com
- 7d agoCue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Developmentfinance.yahoo.com
May 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | Borie Dominique Christian· Chief Medical Officer | Award | 31,500 | $0.00 | $0.00 | filing |
| 2026-07-09 | Garzone Pamela | Award | 21,800 | $0.00 | $0.00 | filing |
| 2026-07-09 | Camardo Daniel A. | Award | 21,800 | $0.00 | $0.00 | filing |
| 2026-07-09 | Sarraf Pasha | Award | 21,800 | $0.00 | $0.00 | filing |
| 2026-07-09 | Meehan Viola Mong | Award | 21,800 | $0.00 | $0.00 | filing |
| 2026-07-09 | Meluzio Michael Vincent· VP, Prin. Accounting Officer | Award | 40,942 | $0.00 | $0.00 | filing |
| 2026-07-09 | Ray Sumita· Chief Legal Compliance Officer | Award | 54,589 | $0.00 | $0.00 | filing |
| 2026-07-09 | Lin Shao-Lee· Chief Executive Officer | Award | 327,537 | $0.00 | $0.00 | filing |
| 2026-05-03 | Lin Shao-Lee· CHIEF EXECUTIVE OFFICER | Award | 327,537 | $0.00 | $0.00 | filing |
| 2025-12-30 | Sarraf Pasha | Buy | 86,947 | $0.32 | $27,596.98 | filing |
| 2025-12-30 | Sarraf Pasha | Buy | 78,116 | $0.31 | $24,325.32 | filing |
| 2025-12-30 | Sarraf Pasha | Buy | 77,417 | $0.30 | $23,348.97 | filing |
| 2025-12-30 | Sarraf Pasha | Buy | 77,148 | $0.30 | $23,167.54 | filing |
| 2025-12-30 | Sarraf Pasha | Buy | 4,229 | $0.31 | $1,308.45 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.